Schistosoma mansoni transient receptor potential melastatin channel (SmTRPM_PZQ) (SmTRPM_PZQ)

The Schistosoma mansoni transient receptor potential melastatin channel (SmTRPM_PZQ) is a calcium-permeable ion channel that serves as the primary molecular target for the anthelmintic drug praziquantel (Park et al., 2019, Science). Located on the parasite's tegument and within its musculature, this channel plays a critical role in maintaining ionic balance and regulating muscle tone (Le et al., 2021, Nature). Upon activation by praziquantel, SmTRPM_PZQ facilitates a massive influx of calcium ions, which triggers immediate muscle paralysis and severe damage to the parasite's protective outer layer (tegument) (UniProt G0W6I4). This disruption allows the host's immune system to recognize and eliminate the worms. While highly effective against adult parasites, the channel's expression or sensitivity varies across life stages, contributing to the drug's reduced efficacy against juvenile schistosomes (Park et al., 2019, Science). Understanding the structure and function of SmTRPM_PZQ is vital for developing next-generation treatments and monitoring for potential drug resistance in endemic regions.

Other names

SmTRP-PZQSmTRPM_PZQPraziquantel-sensitive TRP channelSchistosoma mansoni TRPM channel

Praziquantel acts as an allosteric activator of the SmTRPM_PZQ channel, binding to a specific pocket within the voltage-sensor-like domain to induce a rapid and sustained influx of calcium ions into the parasite's cells (Le et al., 2021, Nature; Park et al., 2019, Science).